Access Program Information
The purpose of this study is to provide expanded access to ASP2215 for subjects with
FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission
(CRc) (complete remission [CR], complete remission with incomplete hematologic recovery
[CRi], complete remission with incomplete platelet recovery [CRp]) with MRD without access
to comparable or alternative therapy.